{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:33:46Z","timestamp":1761197626239,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ipsen"},{"name":"Merz"},{"name":"Auspex"},{"name":"Daiichi Sankyo Pharma"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kyowa"},{"name":"Neurocrine"},{"DOI":"10.13039\/100009655","name":"Sunovion Pharmaceuticals Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Acadia"},{"name":"Accorda"},{"name":"Cynapsus"},{"name":"Neuroderm"},{"name":"Prexton Therapeutics"},{"name":"Intec"},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alexza Pharmaceuticals, Inc"},{"name":"Adamas Pharmaceuticals"},{"name":"US WorldMeds"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.parkreldis.2018.11.025","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T12:10:46Z","timestamp":1543407046000},"page":"146-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Setting the record straight: The nosology of tardive syndromes"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6995-8936","authenticated-orcid":false,"given":"Daniel D.","family":"Truong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Frei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2018.11.025_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.4088\/JCP.tv17016ah4c","article-title":"Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment","volume":"78","author":"Correll","year":"2017","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0447.1964.tb05731.x","article-title":"Neurological symptoms in pharmacotherapy of psychoses","volume":"40","author":"Faurbye","year":"1964","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40265-016-0568-1","article-title":"Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia","volume":"76","author":"Vijayakumar","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib4","article-title":"An update on tardive dyskinesia: from phenomenology to treatment","volume":"3","author":"Waln","year":"2013","journal-title":"Tremor Other Hyperkinet. Mov. (N Y)."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jns.2018.02.005","article-title":"Tardive syndromes","volume":"389","author":"Savitt","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jns.2018.02.008","article-title":"The nosology of tardive syndromes","volume":"389","author":"Frei","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2018.02.009","article-title":"Tardive dyskinesia: out of the shadows","volume":"389","author":"Hauser","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/BF00441188","article-title":"Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy","volume":"1","author":"Uhrbrand","year":"1960","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib9","first-page":"737","article-title":"Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments","volume":"112","author":"Steck","year":"1954","journal-title":"Ann. Med.-Psychol."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib10","first-page":"19","article-title":"Chlorpromazine and neuroleptic treatments in psychiatry","volume":"17","author":"Delay","year":"1956","journal-title":"J. Clin. Exp. Psychopathol."},{"year":"1968","series-title":"Drug-induced Extrapyramidal Syndromes","key":"10.1016\/j.parkreldis.2018.11.025_bib11"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00005053-195610000-00005","article-title":"Psychophysiologic aspects of the new chemotherapeutic drugs in psychiatry; some practical features of neuroleptics in order to screen new drugs","volume":"124","author":"Deniker","year":"1956","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1176\/ajp.113.2.115","article-title":"Complications of chlorpromazine therapy","volume":"113","author":"Cohen","year":"1956","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib14","first-page":"178","article-title":"An unusual syndrome in the oral region caused by administration of megaphen","volume":"27","author":"Kulenkampff","year":"1956","journal-title":"Nervenarzt"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1056\/NEJM195707252570405","article-title":"Complications from the use of tranquilizing drugs","volume":"257","author":"Hollister","year":"1957","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1176\/ajp.114.6.556","article-title":"An interesting reaction to a tranquilizer: tonic seizures with perphenazine (trilafon)","volume":"114","author":"Shanon","year":"1957","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib17","first-page":"35","article-title":"Ein eigentumliches Syndrom im oralen Bereich bei Megaphen Applikation","volume":"28","author":"Schonecker","year":"1957","journal-title":"Nervenarzt"},{"issue":"Suppl","key":"10.1016\/j.parkreldis.2018.11.025_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1176\/ajp.124.8S.40","article-title":"Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature","volume":"124","author":"Crane","year":"1968","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib19","first-page":"550","article-title":"Paroxysmal dyskinesia as the effect of megaphen","volume":"28","author":"Schonecker","year":"1957","journal-title":"Nervenarzt"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib20","first-page":"751","article-title":"[4 Cases of facio-bucco-linguomasticatory dyskinesis of prolonged development following treatment with neuroleptics]","volume":"100","author":"Sigwald","year":"1959","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4088\/JCP.v66n0216","article-title":"Historical comments on tardive dyskinesia: a neurologist's perspective","volume":"66","author":"Paulson","year":"2005","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1176\/ajp.118.6.551","article-title":"Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca","volume":"118","author":"Brandrup","year":"1961","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00005053-196207000-00009","article-title":"Chronic involuntary movements induced by phenothiazines","volume":"135","author":"Druckman","year":"1962","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib24","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/003591576405700835","article-title":"An apparently irreversible syndrome of abnormal movements following phenothiazine medication","volume":"57","author":"Hunter","year":"1964","journal-title":"Proc. Roy. Soc. Med."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/jnnp.27.3.219","article-title":"A syndrome of abnormal movements and dementia in leucotomized patients treated with phenothiazines","volume":"27","author":"Hunter","year":"1964","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib26","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(65)91590-4","article-title":"Persistent oral dyskinesia in treatment with phenothiazine derivatives","volume":"1","author":"Evans","year":"1965","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib27","first-page":"167","article-title":"Drug induced dystonia tarda: treatment with L-dopa","volume":"34","author":"Keegan","year":"1973","journal-title":"Dis. Nerv. Syst."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib28","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/WNL.32.12.1335","article-title":"Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs","volume":"32","author":"Burke","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib29","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/S1353-8020(13)70027-0","article-title":"Acute and subacute drug-induced movement disorders","volume":"20S1","author":"Burkhard","year":"2014","journal-title":"Parkinonsim Relat. Disord."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1056\/NEJM197807272990420","article-title":"Tardive dyskinesia may be only akathisia","volume":"299","author":"Fahn","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mds.870040208","article-title":"Tardive akathisia: an analysis of clinical features and response to open therapeutic trials","volume":"4","author":"Burke","year":"1989","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib32","series-title":"Diagnostic and Statistical Manual of Mental Disorders","first-page":"803","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080012","article-title":"Incidence and severity of tardive dyskinesia increase with age","volume":"39","author":"Johnson","year":"1982","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib34","doi-asserted-by":"crossref","first-page":"31S","DOI":"10.1097\/00004714-198808001-00007","article-title":"The natural history of tardive dyskinesia","volume":"8","author":"Gardos","year":"1988","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib35","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes. Report of the guideline development subcommittee of the American Academy of Neurology","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib36","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","article-title":"Research diagnoses for tardive dyskinesia","volume":"39","author":"Schooler","year":"1982","journal-title":"Arch. Gen. Psychiatr."},{"issue":"Suppl 4","key":"10.1016\/j.parkreldis.2018.11.025_bib37","first-page":"10","article-title":"Prevalence of spontaneous dyskinesia in schizophrenia","volume":"61","author":"Fenton","year":"2005","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib38","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1212\/WNL.28.10.1064","article-title":"Gilles de la Tourette syndrome after long-term chlorpromazine therapy","volume":"28","author":"Klawans","year":"1978","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mds.870070110","article-title":"Tardive tremor","volume":"7","author":"Stacy","year":"1992","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib40","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/mds.870120533","article-title":"Tardive tremor","volume":"12","author":"Storey","year":"1992","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/WNF.0000000000000061","article-title":"Tetrabenazine for tardive tremor in elderly adults: a prospective follow-up study","volume":"38","author":"Kertesz","year":"2015","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib42","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0140-6736(87)92042-3","article-title":"Tardive myoclonus","volume":"1","author":"Tominaga","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib43","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mds.870020408","article-title":"Tardive myoclonus","volume":"2","author":"Little","year":"1987","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib44","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1176\/ajp.146.6.802a","article-title":"Tardive dyskinesia with complaints of pain","volume":"146","author":"Hierholzer","year":"1989","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib45","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.44.11.2115","article-title":"Oral and genital tardive pain syndromes","volume":"44","author":"Ford","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNF.0b013e31818ddbc4","article-title":"Botulinum toxin in painful tardive dyskinesia","volume":"32","author":"Tschopp","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib47","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib48","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.parkreldis.2014.03.024","article-title":"Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism","volume":"20","author":"Morley","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/jnnp.60.2.213","article-title":"Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs","volume":"60","author":"Bocola","year":"1996","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib50","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nrl.2012.05.005","article-title":"Diagnostic accuracy of 123 I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: a prospective study","volume":"28","author":"Olivares Romero","year":"2013","journal-title":"Neurologia"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib51","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.20748","article-title":"[123I]-FP\/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease","volume":"21","author":"Lorberboym","year":"2006","journal-title":"Mov. Disord"},{"key":"10.1016\/j.parkreldis.2018.11.025_bib52","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/archneur.1982.00510220042009","article-title":"Reversible drug-induced parkinsonism. Clinicopathologic study of two cases","volume":"39","author":"Rajput","year":"1982","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib53","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/mds.10202","article-title":"Clinical correlates of the pathology underlying parkinsonism: a population perspective","volume":"17","author":"Bower","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.11.025_bib54","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/mds.26467","article-title":"Neuroleptic-induced parkinsonism: clinicopathological study","volume":"31","author":"Shuaib","year":"2016","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018305224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018305224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:15:57Z","timestamp":1761178557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802018305224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":54,"alternative-id":["S1353802018305224"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.11.025","relation":{},"ISSN":["1353-8020"],"issn-type":[{"type":"print","value":"1353-8020"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Setting the record straight: The nosology of tardive syndromes","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}